Valuation: Pharmigene, Inc.

Market Cap 353M 11.11M 9.91M 9.23M 8.4M 15.83M 1.07B 15.94M 112M 43.41M 546M 41.71M 40.81M 1.76B P/E 2024
-8.68x
P/E 2025 -6.84x
Enterprise Value 922M 29.05M 25.92M 24.15M 21.97M 41.38M 2.8B 41.69M 292M 114M 1.43B 109M 107M 4.59B EV / Sales 2024
10.1x
EV / Sales 2025 5.35x
Free-Float
49.29%
Yield 2024 *
-
Yield 2025 -
1 day-3.62%
1 week+1.84%
Current month+0.42%
1 month-1.78%
3 months+5.12%
6 months-28.91%
Current year-27.47%
1 week 6.8
Extreme 6.8
7.51
1 month 6.7
Extreme 6.7
7.51
Current year 5.9
Extreme 5.9
11.85
1 year 5.9
Extreme 5.9
12.3
3 years 5.9
Extreme 5.9
23.5
5 years 5.9
Extreme 5.9
25.7
10 years 5.9
Extreme 5.9
36
Manager TitleAgeSince
Chief Executive Officer 67 04/11/2019
Chief Operating Officer 49 04/11/2019
Comptroller/Controller/Auditor - -
Director TitleAgeSince
Chairman 67 -
Director/Board Member 35 04/11/2019
Director/Board Member 65 07/08/2020
Change 5-day change 1-year change 3-year change Capi.($)
-3.62%+1.84%-40.41%-69.18% 11.8M
+4.16%+3.04%+49.37%+94.17% 74.16B
-0.37%-3.81%+19.51%+78.12% 57.39B
+1.63%-1.61%+3.16%+36.89% 47.64B
-0.14%+1.99%+341.71%+714.53% 44.29B
+1.93%-2.89%+28.35%+33.02% 42.5B
+0.52%-1.92%+4.48%+110.92% 40.71B
-0.54%+2.93%+9.31%+54.06% 30.97B
+1.56%+4.53%+31.34%+26.92% 28.53B
+0.36%-1.92%-7.59%-11.53% 24.34B
Average +0.52%-0.40%+43.92%+106.79% 39.05B
Weighted average by Cap. +1.25%-0.84%+57.49%+135.58%

Financials

2024 2025
Net sales 117M 3.67M 3.27M 3.05M 2.78M 5.23M 354M 5.27M 36.86M 14.34M 180M 13.78M 13.48M 580M 200M 6.3M 5.62M 5.23M 4.76M 8.97M 606M 9.03M 63.23M 24.6M 309M 23.64M 23.13M 995M
Net income -82.86M -2.61M -2.33M -2.17M -1.97M -3.72M -251M -3.75M -26.21M -10.2M -128M -9.8M -9.59M -412M -73M -2.3M -2.05M -1.91M -1.74M -3.27M -221M -3.3M -23.09M -8.98M -113M -8.63M -8.44M -363M
Net Debt 458M 14.42M 12.87M 11.99M 10.91M 20.54M 1.39B 20.69M 145M 56.35M 709M 54.14M 52.97M 2.28B 570M 17.94M 16.01M 14.91M 13.57M 25.55M 1.73B 25.74M 180M 70.1M 882M 67.35M 65.9M 2.83B
Logo Pharmigene, Inc.
Pharmigene Inc is mainly engaged in drug gene diagnosis, functional medical testing services and agency sales of laboratory equipment and consumables. The Company mainly engages in field of genomics science, developing professional drug genetic diagnostic kits, testing technologies, and overall solutions for the research and development of drug genomics in precision medicine. The Company's molecular diagnostic products mainly include AutoEx16 automatic nucleic acid extractor, Clopidogrel drug effectiveness gene CYP2C19*2&*3 test kit, SGE 1502 test suite, SGE 3101 test suite, SGE 5701 test suite, Sega 5801 test kit, SGE B27 test kit, SGE whole blood calculation and extraction kit and others. Testing services include drug genetic testing projects, functional medical testing projects and personalized genetic testing. The Company mainly distributes its products in Taiwan market and other markets.
Employees
-
Date Price Change Volume
05/10/26 NT$7.180 -3.62% 16,032
02/10/26 NT$7.450 +4.20% 80,560
01/10/26 NT$7.150 0.00% 11,010
30/09/26 NT$7.150 +0.85% 13,021
  1. Stock Market
  2. Stocks
  3. 7595 Stock